ZVRA · NASDAQ · Biotechnology

Zevra Therapeutics (ZVRA)

Commercializes U.S.-approved therapies for Niemann-Pick type C disease and certain urea-cycle disorders.

$11.16
vs last close−0.42 (−3.59%)